



NSX ANNOUNCEMENT

30 March 2026

ENTRY INTO SHARE SALE AND PURCHASE AGREEMENT AND SOFTWARE LICENCE ARRANGEMENT

GO-Dx Corporation (Aust) Ltd (**GD8** or the **Company**) is pleased to announce that it has entered into a Share Sale and Purchase Agreement and Supplementary Agreement (together 'the **Agreement**') with Mr Chin Hua Peh (**Seller**), pursuant to which GD8 proposes to acquire shares representing 27.5% of the issued share capital of White Lingjun Pte Ltd (UEN 202216756D) (**Target Company** or **White Lingjun**), (the **Proposed Transaction**).

White Lingjun is a private company incorporated in Singapore. Its sole wholly owned subsidiary Dongguan Lingjun Silicone Products Co. Ltd is a private company incorporated in the Republic of China, and generates revenue from the development and manufacture of artificial intelligence (AI) Humanoid hardware products with proprietary technology, selling whole silicone human bodies or components in the form of silicone body parts.

In addition, to complement its investment in White Lingjun, GD8 has entered into a Special Declaration with White Lingjun for

[i] usage rights to certain medical robotics software developed by Beijing Qianshou Robotics Technology and Culture Co. Ltd. (**Beijing**) and granted to White Group Pte Ltd (**White Group**), then granted by White Group to White Lingjun, &

[ii] an exclusive three year sales and operations license for the medical robotics software in the territories of Australia and New Zealand effective from 1 December 2025.
(**Software Licence Arrangement**).

Material Terms of the Agreement

The material terms of the Agreement are as follows:

- 1. Consideration:** The total consideration for the sale shares shall be the issuance and allotment of up to 133,255,440 ordinary shares in the capital of GD8 (**Consideration Shares**) to the Seller (or its permitted nominee). Based on a deemed issue price of AUD \$0.15 per share, the total aggregate value of the Consideration Shares is AUD \$19,988,316.

The determination of the consideration and its value has been supported by an independent valuation of the Target Company and its assets performed by Lim and Young Appraisal Pte Ltd for GD8.

- 2. Issuance of Consideration Shares:** The Consideration Shares shall be issued in two tranches as follows:

- (a) Tranche 1 (Initial Consideration):** 60,000,000 Consideration Shares to be issued and allotted to the Seller immediately upon, and subject to Completion.

- (b) **Tranche 2 (Performance-Linked Consideration):** 73,255,440 Consideration Shares to be issued upon the Target Company (or the Seller) procuring no less than USD \$20,000,000 in external investment capital (whether via equity, debt, shares subscription facility or a combination thereof) or in the form of a legally binding Term Sheet Agreement offer of no less than USD \$20,000,000 for GD8 within two (2) months of the Completion Date.
3. **Expected Completion:** Completion shall occur within sixty (60) days and, in any event, no later than 10 May 2026, subject to GD8 obtaining the relevant approvals.
4. **Board Nomination Right:** GD8 has the right to nominate for appointment one (1) director to the board of the Target Company. GD8 will appoint Mr Lim Kah Meng as director to the board of the Target Company.
5. **Restricted Securities:** After Completion, the Consideration Shares may be classified as 'restricted securities' pursuant to the NSX Listing Rules and subject to mandatory escrow.

Conditions Precedent and Approvals

Completion of the Proposed Transaction is subject to the satisfaction of certain conditions precedent including (but not limited to):

1. GD8 obtaining all necessary regulatory approvals, including approvals required under NSX Listing Rules and the Corporations Act 2001 (Cth); and
2. GD8 obtaining all necessary shareholder approvals for the Proposed Transaction.

GD8 intends to take all reasonable steps to obtain the relevant approvals required to carry out the Proposed Transaction.

Details of the extraordinary general meeting (**EGM**) to seek shareholder approval for the Proposed Transaction will be announced in due course.

Related Party Transaction

The Company advises that the Seller, Mr Chin Hua Peh, a current director of GD8, also holds 30.67% of the shares in GD8 and is therefore a substantial shareholder in GD8.

By virtue of the Proposed Transaction, the Seller's shareholding in GD8 will increase up to:

- (a) 49.32% following Tranche 1; and
- (b) 61.86% following Tranche 2.

Software Licence Arrangement

In connection with the Proposed Transaction, GD8 has entered into a Software Licence Arrangement with White Lingjun regarding the licensing of certain medical robotics software.

White Group holds a 70% equity stake in Beijing, with the remaining 30% held by Ms Liu Ying (representing Dongguan Lingjun Silicone Co., Ltd.), Professor Zhang Wei and others. White Group has granted White Lingjun the usage rights to certain medical robotics software developed by Beijing.

Material Terms of the Software Licence Arrangement

The material terms of the Software Licence Arrangement are as follows:

1. **Licence Grant:** It is confirmed that White Group has granted to White Lingjun usage rights in certain medical robotics software developed by Beijing limited to the following applications: hospital robotic software for obstetric patient simulators and infant simulators, prosthetic hand software for factory and motor vehicle accident-related palm amputations, lower leg and foot prosthetic software, ear/nose/eye prosthetic software, and robotic pet software (**Software Applications**).
2. White Lingjun grants GD8 an exclusive sales and operation licence for certain medical robotics software limited to the Software Applications.
3. **Territory:** The exclusive licence is limited to Australia and New Zealand only.
4. **Consideration:** The licence is granted for nil monetary payment, however in consideration for the grant, GD8 shall provide White Lingjun with data collection and feedback to support research, analysis and conceptual development of the software by Beijing.
5. **Term and Conditions:** The terms of the exclusive sales and operation licence are to be negotiated in a separate agreement after NSX, ASIC and shareholder approval at the EGM in favour of the Proposed Transaction. The sales and operation licence have a term of three (3) years commencing on 1 December 2025, with the possibility of extension or variation by mutual agreement of the parties subject to satisfactory business performance and cooperation.
6. **IP and Manufacturing Rights:** GD8 shall not possess any manufacturing rights or intellectual property rights in respect of the software. Should GD8 require manufacturing rights, it must submit a formal application to White Group and may only proceed upon receiving written approval.
7. **Exclusivity Obligations:** During the term of the exclusive licence, GD8 shall not sell or act as agent for any similar products in the licensed territories.
8. **Governing Law:** The Software Licence Arrangement is governed by and subject to the jurisdiction of Singapore.

About GO-Dx Corporation (Aust) Ltd

GD8 is a publicly listed company incorporated in Australia, with its shares admitted to quotation on the National Stock Exchange of Australia. GD8 owns 100% of the shares in GO-Dx Corporation Ltd (UEN 201925421H), a company incorporated in Singapore in the medical diagnostics and diagnostics technology sectors of the healthcare industry, pioneering development and innovation with regard to personalised Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular, immunity, anti-ageing, neural health and specific cancers.

Dr KM Lim
Managing Director